{
  "trial_id": "NCT01114438",
  "trial_group": "diabetes",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, Gender, Duration of Type 2 Diabetes, HbA1c level, Type 2 Diabetes medications, BMI, Post-menopausal status, Contraceptive use, Insulin dosage, Fasting C Peptide serum level, History of ketoacidosis, NSAID use, Prescription anticoagulation therapy use, History of iron deficiency anemia, History of GI tract abnormalities, Presence of symptomatic gallstones or kidney stones, Known infection status, History of coagulopathy, History of upper gastro-intestinal bleeding conditions, Psychological characteristics, History of GI surgery, Active H. pylori status, Family history of autoimmune connective tissue disorders, Presence of active and uncontrolled GERD, Liver function (serum creatinine level), Dentition status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Gender"
        ],
        [
          "BMI",
          "BMI"
        ],
        [
          "Duration of Diabetes",
          "Duration of Type 2 Diabetes"
        ],
        [
          "Baseline HbA1c",
          "HbA1c level"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Region of Enrollment",
        "Weight (kg)",
        "Baseline glucose"
      ],
      "remaining_candidate_features": [
        "Type 2 Diabetes medications",
        "Post-menopausal status",
        "Contraceptive use",
        "Insulin dosage",
        "Fasting C Peptide serum level",
        "History of ketoacidosis",
        "NSAID use",
        "Prescription anticoagulation therapy use",
        "History of iron deficiency anemia",
        "History of GI tract abnormalities",
        "Presence of symptomatic gallstones or kidney stones",
        "Known infection status",
        "History of coagulopathy",
        "History of upper gastro-intestinal bleeding conditions",
        "Psychological characteristics",
        "History of GI surgery",
        "Active H. pylori status",
        "Family history of autoimmune connective tissue disorders",
        "Presence of active and uncontrolled GERD",
        "Liver function (serum creatinine level)",
        "Dentition status"
      ]
    },
    "processed-gen-response": "Age, Gender, Duration of Type 2 Diabetes, HbA1c level, Type 2 Diabetes medications, BMI, Post-menopausal status, Contraceptive use, Insulin dosage, Fasting C Peptide serum level, History of ketoacidosis, NSAID use, Prescription anticoagulation therapy use, History of iron deficiency anemia, History of GI tract abnormalities, Presence of symptomatic gallstones or kidney stones, Known infection status, History of coagulopathy, History of upper gastro-intestinal bleeding conditions, Psychological characteristics, History of GI surgery, Active H. pylori status, Family history of autoimmune connective tissue disorders, Presence of active and uncontrolled GERD, Liver function (serum creatinine level), Dentition status."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Duration of Type 2 Diabetes, Baseline HbA1c, Body Mass Index, Total Daily Insulin Dose, Use of Oral Diabetes Medications, Systolic Blood Pressure, Diastolic Blood Pressure,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "Duration of Diabetes",
          "Duration of Type 2 Diabetes"
        ],
        [
          "Baseline HbA1c",
          "Baseline HbA1c"
        ],
        [
          "BMI",
          "Body Mass Index"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Weight (kg)",
        "Baseline glucose"
      ],
      "remaining_candidate_features": [
        "Total Daily Insulin Dose",
        "Use of Oral Diabetes Medications",
        "Systolic Blood Pressure",
        "Diastolic Blood Pressure"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Duration of Type 2 Diabetes, Baseline HbA1c, Body Mass Index, Total Daily Insulin Dose, Use of Oral Diabetes Medications, Systolic Blood Pressure, Diastolic Blood Pressure"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "##Answer:\nAge, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Diabetes duration, HbA1c, BMI, Systolic Blood Pressure, Diastolic Blood Pressure, Type 2 Diabetes medications, Insulin dose, Menopausal status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "BMI",
          "BMI"
        ],
        [
          "Duration of Diabetes",
          "Diabetes duration"
        ],
        [
          "Baseline HbA1c",
          "HbA1c"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Region of Enrollment",
        "Weight (kg)",
        "Baseline glucose"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Region of Enrollment",
        "Systolic Blood Pressure",
        "Diastolic Blood Pressure",
        "Type 2 Diabetes medications",
        "Insulin dose",
        "Menopausal status."
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Diabetes duration, HbA1c, BMI, Systolic Blood Pressure, Diastolic Blood Pressure, Type 2 Diabetes medications, Insulin dose, Menopausal status."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, BMI, duration of type 2 diabetes, HbA1c level, type 2 diabetes medications, insulin use, metformin use, fasting C-peptide serum level, history of ketoacidosis, history of GI surgery, history of H. pylori, history of autoimmune connective tissue disorder, presence of gastroesophageal reflux disease, liver function, kidney function, SF 36v2 Quality of Life Assessment at baseline.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "BMI",
          "BMI"
        ],
        [
          "Duration of Diabetes",
          "duration of type 2 diabetes"
        ],
        [
          "Baseline HbA1c",
          "HbA1c level"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Region of Enrollment",
        "Weight (kg)",
        "Baseline glucose"
      ],
      "remaining_candidate_features": [
        "type 2 diabetes medications",
        "insulin use",
        "metformin use",
        "fasting C-peptide serum level",
        "history of ketoacidosis",
        "history of GI surgery",
        "history of H. pylori",
        "history of autoimmune connective tissue disorder",
        "presence of gastroesophageal reflux disease",
        "liver function",
        "kidney function",
        "SF 36v2 Quality of Life Assessment at baseline."
      ]
    },
    "processed-gen-response": "Age, sex, BMI, duration of type 2 diabetes, HbA1c level, type 2 diabetes medications, insulin use, metformin use, fasting C-peptide serum level, history of ketoacidosis, history of GI surgery, history of H. pylori, history of autoimmune connective tissue disorder, presence of gastroesophageal reflux disease, liver function, kidney function, SF 36v2 Quality of Life Assessment at baseline."
  }
}